Gongwin Biopharm Holdings Co., Ltd. AI Stock Analysis
Gongwin Biopharm Holdings Co., Ltd. (6617) AI Stock Analysis
Gongwin Biopharm Holdings Co., Ltd.
(TPEx:6617)
The overall score is severely depressed by the company's dire financial state, marked by collapsing revenues and massive cash burn. While the stock shows some positive technical momentum, the fundamental business is in crisis. The negative P/E ratio further confirms a lack of earnings power, making the stock a high-risk proposition.
Gongwin Biopharm Holdings Co., Ltd. (6617) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 15.02B
- Dividend Yield
- ―
- Average Volume (3M)
- 866.74K
- Price to Earnings (P/E)
- -103.7
- Beta (1Y)
- 0.99
- Revenue Growth
- 11.66%
- EPS Growth
- -72.96%
- Country
- TW
- Employees
- 20
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Distribution
Gongwin Biopharm Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concl...
Gongwin Biopharm Holdings Co., Ltd. Financial Statement Overview
Summary
Financial performance is critically weak. The income statement shows a -92.8% revenue collapse and a -358.8% net margin. Cash flow is deeply negative with a -$188.9M free cash flow, and the balance sheet equity is eroding rapidly. The only minor positive is low debt, but it is insufficient to offset the severe operational distress.
Income Statement
8Very NegativeBalance Sheet
45NeutralCash Flow
5Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.83M | 36.45M | 32.04M | 18.91M | 1.14M | 1.14M |
| Gross Profit | 9.41M | 14.99M | 8.68M | 11.20M | 1.07M | 1.08M |
| EBITDA | -280.24M | -196.19M | -75.97M | -81.05M | -275.56M | -100.58M |
| Net Income | -150.10M | -114.13M | -82.55M | -92.04M | -254.19M | -121.58M |
Balance Sheet | ||||||
| Total Assets | 2.58B | 2.80B | 3.38B | 1.52B | 1.62B | 1.17B |
| Cash, Cash Equivalents and Short-Term Investments | 1.65B | 1.82B | 2.39B | 1.08B | 1.32B | 909.82M |
| Total Debt | 150.78M | 129.74M | 126.75M | 77.17M | 141.74M | 115.14M |
| Total Liabilities | 310.54M | 279.20M | 281.84M | 203.53M | 248.70M | 184.43M |
| Stockholders Equity | 2.28B | 2.53B | 3.11B | 1.32B | 1.39B | 970.72M |
Cash Flow | ||||||
| Free Cash Flow | -188.87M | -138.21M | -293.54M | -111.93M | -238.37M | -95.56M |
| Operating Cash Flow | -186.41M | -135.75M | -87.41M | -110.80M | -232.20M | -95.51M |
| Investing Cash Flow | -322.69M | 600.68M | -1.20B | -280.97M | -202.00M | -246.42M |
| Financing Cash Flow | -88.47M | -388.61M | 1.88B | -12.10M | 604.05M | 101.77M |
Gongwin Biopharm Holdings Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TW:6617, the sentiment is Positive. The current price of 125.00 is above the 20-day moving average (MA) of 115.80, above the 50-day MA of 123.71, and above the 200-day MA of 90.06, indicating a bullish trend. The MACD of 1.32 indicates Negative momentum. The RSI at 57.06 is Neutral, neither overbought nor oversold. The STOCH value of 89.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TW:6617.
Gongwin Biopharm Holdings Co., Ltd. Peers Comparison
Overall Rating
TW:172073Outperform
TW:411461Neutral
TW:661744Neutral
TW:657642Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | TWD 10.87B | 10.84 | ― | 3.62% | 4.62% | 9.56% | |
| 61Neutral | TWD 14.35B | 17.11 | ― | 3.18% | 20.99% | 5.70% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 44Neutral | TWD 16.26B | -103.66 | ― | ― | 11.66% | -72.96% | |
| 42Neutral | TWD 11.26B | 510.71 | ― | ― | 6.41% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6617 | Gongwin Biopharm Holdings Co., Ltd. | 125.00 | 47.30 | 60.88% | |
| TW:1720 | Standard Chemical & Pharmaceutical Co. Ltd. | 55.10 | -0.28 | -0.51% | |
| TW:4114 | Synmosa Biopharma Corp | 26.55 | -1.92 | -6.75% | |
| TW:6467 | TAHO Pharmaceuticals Ltd | 231.00 | 61.00 | 35.88% | |
| TW:6576 | Foresee Pharmaceuticals Co., Ltd. | 70.60 | -5.10 | -6.74% | |
| TW:6589 | EirGenix, Inc. | 53.00 | -19.80 | -27.20% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026
